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Abstract
Aims: To find specific magnetic resonance imaging (MRI) features to differentiate metastatic ovarian tumors from
primary epithelial ovarian cancers.
Methods: Eleven cases with metastatic ovarian tumors and 26 cases with primary malignant epithelial ovarian cancers
were retrospectively studied. All features such as patient characteristics, MRI findings and biomarkers were evaluated.
The differences including laterality, configuration, uniformity of locules, diffusion weighted imaging (DWI) signal of solid
components and enhancement of solid portions between metastatic ovarian tumors and primary epithelial
ovarian cancers were compared by Fisher’s exact test. Median age of patients, the maximum diameter of
lesions and biomarkers were compared by the Mann-Whitney test.
Results: Patients with metastatic ovarian tumors were younger than patients with primary epithelial ovarian
cancers in the median age (P = 0.015). Patients with bilateral tumors in metastatic ovarian tumors were more
than those of primary epithelial ovarian cancers (P = 0.032). The maximum diameter of lesions in metastatic
ovarian tumors was smaller than that of primary epithelial ovarian cancers (P = 0.005). The locules in metastatic ovarian
tumors were more uniform than those of primary epithelial ovarian cancers (P = 0.024). The enhancement of
solid portions in metastatic ovarian tumors showed more moderate than that of primary epithelial ovarian
cancers (P = 0.037). There was no statistically significant difference between the two groups in configuration,
DWI signal of solid components and ascites. Biomarkers such as CA125 and human epididymis protein 4
(HE4) in metastatic ovarian tumors showed less elevated than that of primary epithelial ovarian cancers.
Conclusions: Significant differences between metastatic ovarian tumors and primary epithelial ovarian cancers
were found in the median age of patients, laterality, the maximum diameter of lesions, uniformity of locules,
enhancement patterns of solid portions and biomarkers. Metastatic ovarian tumors usually presented in the
younger patients, smaller-sized, more bilateral lesions, more uniform of locules, more moderate enhancement
of solid portions, and less elevated levels of CA125 and HE4 than those of primary epithelial ovarian cancers.
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Background
The optimal management and prognosis of metastatic
ovarian tumors depend on the origin of the primary tumor
[1, 2]. For primary ovarian cancers, management will be
based on cytoreductive surgery and systemic therapy (de-
pending on stage). Therefore, preoperative discrimination
is very critical. However, by now, it is difficult to discrimin-
ate these tumors by imaging, or even by histopathology in
some cases, as macroscopic and microscopic features of
metastatic ovarian tumors and primary epithelial ovarian
cancers are often similar. Therefore, they cannot be defini-
tively classified without further clinical evaluations [3, 4].
Histological preoperative diagnosis is now and then im-
possible because there is a risk of dissemination of primary
ovarian cancer on an early stage otherwise. In general, the
therapy methods and prognoses of metastatic ovarian
tumors are different from those of primary epithelial
ovarian cancers [5]. Therefore, discriminations between
them are very critical. However, there is a lack of com-
prehensive imaging studies concerning the distinctions.
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Magnetic resonance imaging (MRI) is a useful tool for
investigation and description of characteristic signs for
the preoperative diagnosis of an ovarian lesion [1]. The
object of this study is to detect specific MRI features of
metastatic ovarian tumors that can be discriminated
from primary epithelial ovarian cancers.
Methods
Study subjects
This retrospective study was approved by the institu-
tional review boards of Shanghai First People’s Hospital,
Shanghai, China. The informed consent requirement was
waived. We searched for data of patients with ovarian tu-
mors from January 2012 to December 2014 on a hospital
information system—a picture archiving and communica-
tion system (PACS). We encountered 11 consecutive cases
(median age, 42 years; range, 21–58 years) of metastatic
ovarian tumors confirmed by pathology. Six gastric can-
cers, two colon cancers, one cervical cancer, one breast
cancer and one thyroid cancer were found among the pa-
tients. It is obvious that the most common site of primary
origin of metastatic ovarian cancers was stomach. Mean-
while, we detected 26 consecutive cases (median age,
56 years; range, 17–82 years) with pathologically confirmed
primary epithelial ovarian cancers. None of these cases wit-
nessed the history of malignant tumors except the present
cancers. All the primary epithelial ovarian cancers had
undergone surgery. Then the cancers were confirmed by
histopathological pathologists in Shanghai First People’s
Hospital. Consequently, ten serous cystadenocarcinoma,
six clear cell cancers, five borderline malignancy, three
mucinouscystadenocarcinoma and two endometrioid
adenocarcinomas were found (Table 1).
MRI scanning
MRI examinations were performed on a 3T system (Signa
HD, General Electric Healthcare, Milwaukee, WI, USA).
The scan scope was from the umbilicus to the pubic sym-
physis in the caudocranial direction. For too large lesions
to be totally scanned on axial imaging, a sagittal scanning
sequence was adopted to contain as much of the total le-
sion as possible. First, routine MRI protocols were per-
formed for the detection of the lesions, which contained
fast spin-echo (FSE) T1-weighted images (T1WI), sagit-
tal FSE T2-weighted images (T2WI) and fat-suppressed
T2WI (FS T2WI) on the axial imaging. A diffusion
weighted imaging (DWI)-MRI sequence contained an
echo-planar imaging sequence with an array spatial-
sensitivity-encoding technique (ASSET). The settings of
the T1WI MRI protocol were: repetition time (TR) =
540 ms; echo time (TE) = 7 ms; number of excitations
(NEX) = 2 and thickness = 7 mm. The parameters of the
T2WI MRI protocol were: TR = 2400 ms; TE = 85 ms;
NEX = 1 and thickness = 7 mm. The settings of the FS
T2WI MRI protocol were: TR = 3800 ms; TE = 90 ms;
NEX = 2 and thickness = 7 mm. The settings of the
DWI MRI protocol were: TR = 4300 ms; TE = 63 ms;
NEX = 6; thickness = 7 mm and the b value = 0 or 800 s/
mm2. Second,a liver acquisition with a volume acceleration
(LAVA) sequence was adopted for contrast-enhanced pel-
vic imaging, and a power injector (Missouri Ulrich, Ulm,
Germany) was used to inject the contrast medium (Magne-
vist, Bayer Schering Pharma AG, Germany). The parame-
ters of the LAVA MRI protocol were: TR = 3.5 ms; TE =
1.6 ms; NEX = 1; flip angle = 15°; band width =125 kHz
and thickness = 2 mm. Subsequently, the images were ob-
tained in multiple phases of contrast agent enhancement
among the sagittal and axial planes—precontrast sagittal
and axial oblique, postcontrast at 20 s, 40 s, 60 s, 80 s in
the axial plane, and 120 s in the sagittal plane. The details
of the scanning parameters of imaging are presented in
Table 2.
MRI image analysis
The following lesion parameters were evaluated: 1) the
maximum diameter of lesions; 2) laterality; 3) uniformity
of locules (uniform or not uniform); 4) configuration:
cystic-solid (less than half of solid component), solid
(more than half of solid component); 5) DWI signal of
solid components (moderate or high); 6) enhancement
of solid portions (moderate or prominent enhancement,
referring to the enhancement of myometrium); 7) asci-
tes. The preoperative MRI diagnoses were correlated
with histopathological results.
Table 1 Summary of the cases




Gastric cancer 6 6
Colon cancer 2 2
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Statistical analyses
Statistical analyses were performed with SPSS 19.0 for
Windows (SPSS, Chicago, IL). The differences between
metastatic ovarian tumors and primary epithelial ovarian
cancers in laterality, configuration, uniformity of locules,
DWI signal of solid components, and enhancement of solid
portions were compared by Fisher’s exact test, Median age
of patients, the maximum diameter of lesions and bio-
markers (CA125, human epididymis protein 4 (HE4)) were
compared by the Mann-Whitney test. The sensitivity, spe-
cificity, accuracy, positive predictive value (PPV), and nega-
tive predictive value (NPV) of the significant MRI features
of metastatic ovarian tumors were calculated. P < 0.05 was
considered statistically significant.
Results
Metastatic ovarian tumors and primary epithelial ovarian
cancers were found in the median patients who were 42
and 56 years old respectively (P = 0.015). Totally, seventeen
tumors were found in 11 patients with metastatic ovarian
tumors—bilateral tumors in six patients and unilateral tu-
mors in five patients; thirty-one tumors were found in 26
patients with primary epithelial ovarian cancers—bilateral
tumors in five patients and unilateral tumors in 21 patients
(P = 0.032). The maximum tumor diameter was generated
from 25 to 200 mm (median, 67 mm) in metastatic ovarian
tumors versus 16 to 285 mm (median, 122 mm) in primary
epithelial ovarian cancers (P = 0.005). The locules were uni-
form in 59 % of metastatic ovarian tumors versus 26 % of
primary epithelial ovarian cancers (P = 0.024). The en-
hancement of solid portions was moderate in 76 % of
metastatic ovarian tumors versus 45 % in primary epithelial
ovarian cancers (P = 0.037). Figure 1 showed that the loc-
ules of a serous cystadenocarcinoma on the right ovary
were not uniform on FS T2WI and the solid portion was
prominent enhancement on LAVA dynamic contrast-
enhanced MRI (DCE-MRI) (A and C). In contrast, the
locules of a metastatic ovarian tumors on the right
ovary were uniform on FS T2WI and the solid portion
was moderate enhancement on LAVA DCE-MRI (B
and D). CA125 and HE4 of metastatic ovarian tumors
and primary epithelial ovarian cancers were significantly
different (P = 0.033, 0.006, respectively). In all, there was a
statistically significant difference in the median age of
patients, the maximum diameter of lesions, laterality,
uniformity of locules, enhancement of solid components,
CA125 and HE4 between metastatic ovarian tumors and
primary epithelial ovarian cancers. There was no statisti-
cally significant difference between the two groups in terms
of configuration, DWI signal of solid components and asci-
tes (P = 0.272, 0.428 and 0.108, respectively). The MRI fea-
tures of metastatic ovarian tumors compared with primary
epithelial ovarian cancers are shown in Table 3.
Diagnostic parameters for the characterization of the
metastatic ovarian tumors are listed in Table 4. The com-
bination of ovarian lesions with any one of the following
three features, patients’ age, small size, and bilaterality,
yielded sensitivity, specificity, accuracy, PPV, and NPV for
identifying metastatic ovarian tumors of 100, 87, 92, 89,
and 100 %, respectively.
Discussion
It is important to discriminate between metastatic ovarian
tumors and primary ovarian cancers to select the most ap-
propriate management which influences the prognosis.
However, it is difficult to distinguish those two groups of
tumors because they both show the imaging features of
malignant tumors. There are some studies concerning the
imaging features of metastatic ovarian tumors. Metastatic
ovarian tumors and primary epithelial ovarian cancers are
difficult to distinguish by CT as they both display mixed
cystic and solid lesions [6]. Bilaterality has been reported as
a specific feature of metastatic ovarian tumors [7]. How-
ever, La Fianza et al concluded that bilaterality was not sig-
nificantly different between secondary and primary ovarian
cancers after reviewing more than eighty cases of ovarian
tumors [8]. In our study, 54.5 % of metastatic tumors
showed bilaterality in contrast to 23.8 % of primary epithe-
lial ovarian cancers (P = 0.032), roughly in agreement with
Kim et al. [7]. Therefore, bilaterality still seems to be an im-
portant factor in diagnosing metastatic ovarian tumors by
imaging.
Khunamornpong et al reported that the maximum diam-
eter of unilateral ovarian carcinomas less than 100 mm
were considered as metastases, and more than 100 mm as
primary ovarian cancers [4]. Jung et al advocated that a cut-
off of 150 mm for classifying unilateral tumors resulted in a
higher diagnostic accuracy [5]. In our study, the median
Table 2 Details of parameters for MRI scanning protocols
Parameters FSE-T1WI FSE-T2WI FS T2WI EPI-DWI LAVA
Repetition/echo time (ms) 540/7 2400/85 3800/90 4300/63 3.5/1.6
NEX 2 1 2 6 1
Thickness(mm) 7 7 7 7 2
Field of view (mm) 36 36 36 40 38
Matrix 320 × 224 256 × 224 256 × 224 96 × 130 320 × 224
Flip angle (degrees) 15
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Table 3 Comparison of each parameter between metastatic and primary ovarian tumors
Metastatic Primary P value
Patients’ age (years) Median 42 56 0.015
Laterality Unilateral cases 5 21 0.032
Bilateral cases 6 5
Maximum diameter of lesions (mm) Median 67 122 0.005
Uniformity of locules Uniform 10 8 0.024
Not uniform 7 23
Configuration Cystic-solid 10 23 0.272
Solid 7 8
DWI signal of solid components Intermediate 5 6 0.428
High 12 25
Enhancement of solid portions Moderate 13 14 0.037
Prominent 4 17
CA125 Elevated cases 3 17 0.033
HE4 Elevated cases 1 15 0.006
Ascites 5 19 0.108
Fig. 1 a and c A 58-year-old woman with serous cystadenocarcinoma on the right ovary. a Axial T2WI with fat saturation image showed the locules
were not uniform. c Axial LAVA dynamic contrast-enhanced MRI image showed the solid portion was prominent enhancement (arrowhead).
b and d: A 49-year-old woman with metastatic ovarian tumors on the right ovary. b Axial T2WI with fat saturation image showed the
locules were uniform. d Axial LAVA dynamic contrast-enhanced MRI image showed the solid portion was moderate enhancement (arrow)
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maximum tumor diameter is 101 mm in unilateral meta-
static ovarian tumors versus 154 mm in primary epithelial
ovarian cancers. Perhaps, the maximum diameter of tu-
mors ranged from100 to 150 mm may be an overlap area
between unilateral metastatic ovarian tumors and primary
ovarian cancers.
Tanaka et al. reported that metastatic ovarian tumors
tended to be composed of uniform cysts compared with
primary mucinous tumors [2]. Our results suggested that
metastatic ovarian tumors tend to be composed of uniform
locules in contrast to primary epithelial ovarian cancers,
which is similar to Tanaka et al. [2]. Histopathological find-
ings show that metastatic tumors proliferate in a more uni-
form manner than primary ovarian cancers [2]. We think
that features such as mucus productivity of tumor cells
may be more uniform in metastatic tumors. Consequently,
this could explain that the size of locules with metastatic
ovarian tumors would be more uniform than those of pri-
mary epithelial ovarian cancers.
Primary ovarian neoplasms often appeared as a promin-
ent enhancement [9–12]. Our study was also in accordance
with previously reported studies. Our study advocated that
metastatic ovarian tumors often appeared as a moder-
ate enhancement versus primary epithelial ovarian can-
cers with a prominent enhancement.
DWI-MRI evaluation of ovarian tumors has yet been re-
ported as a useful tool for differentiating malignant tumors
from benign ovarian lesions [13–18]. However, there is no
helpful role for distinguishing two types of malignant tu-
mors by DWI-MRI. Moreover, there was no statistically
significant difference between the two groups in terms of
DWI signal of solid components. Besides, there was
also no statistically significant difference between the
two groups in terms of presence of ascites.
For other features, the patients of metastatic ovarian tu-
mors were younger than those of primary epithelial ovarian
cancers. This is possibly due to the younger population of
some kinds of cancers recently. In one series of gastric can-
cers in young women (age < 36 years), 55 % had ovarian in-
volvement [19]. Thus, in a woman with a known gastric
carcinoma, the development of bilateral ovarian masses on
imaging will be considered as highly likely to be secondary
metastases rather than primary ovarian cancers. CA125
and HE4 are significantly higher in primary ovarian cancers
than metastatic ovarian tumors. But, the level of CA125
and HE4 are not correlated to the size of the lesions, which
is corresponded by Liao et al. [20].
There were some limitations in our study. First, a lim-
ited number of patients were studied. Therefore, more
cases are needed to further investigate the value of these
imaging features for diagnosing metastatic ovarian tu-
mors. Second, the interreader variability was not evalu-
ated. Third, a selection bias was inevitably appeared as
the retrospective inherent nature of the study.
Conclusions
In conclusion, metastatic ovarian tumors seem to be
smaller in size, more bilateral, more uniform in locules and
more moderate enhancement in solid portions than those
of primary ovarian cancers. Metastatic ovarian tumors were
with less elevated levels of CA125 and HE4 in contrast with
primary ovarian cancers. Although the sensitivity, specifi-
city, and accuracy of any features are not sufficient for diag-
noses, the combination of three key features (patients’ age,
small size, and bilaterality) tends to have a high sensitivity,
specificity, and accuracy for identifying metastatic ovarian
tumors. The radiologist must depend on a combination of
the imaging features as well as the clinical examinations in
order to diagnose metastatic ovarian tumors.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Guarantor of integrity of entire study, GFZ; study design or data acquisition
or data interpretation, all authors; manuscript drafting or manuscript revision
for important intellectual content, GFZ, YHX; approval of final version of
submitted manuscript, all authors; literature research, YHX; clinical studies,
GFZ, YHX; statistical analysis, YHX; and manuscript editing, YHX, JY. All
authors read and approved the final manuscript.
Acknowledgments
This research is financially supported by Technology Commission of
Shanghai Municipality (11JC1410500).
Published disclosure
The authors report no disclosure of interest in this work.
Received: 5 January 2015 Accepted: 25 August 2015
References
1. Willmott F, Allouni KA, Rockall A. Radiological manifestations of metastasis
to the ovary. J Clin Pathol. 2012;65:585–90.
Table 4 Accuracy of MRI in characterizing ovarian lesions as metastatic ovarian tumors
MRI features Sensitivity (%) Specificity (%) Accuracy (%) PPV (%) NPV (%)
Patients’ age(<50 years) 65 (11/17) 81 (25/31) 75 (36/48) 65 (11/17) 81 (25/31)
Small size (<100 mm) 82 (14/17) 61 (19/31) 69 (33/48) 54 (14/26) 86 (19/22)
Bilaterality 71 (12/17) 68 (21/31) 69 (33/48) 55 (12/22) 81 (21/26)
Uniformity of locules 59 (10/17) 74 (23/31) 69 (33/48) 50 (10/20) 77 (23/30)
Moderate enhancement 76 (13/17) 55 (17/31) 63(30/48) 48 (13/27) 81 (17/21)
PPV positive predictive value, NPV negative predictive value
Xu et al. Journal of Ovarian Research  (2015) 8:61 Page 5 of 6
2. Tanaka YO, Okada S, Satoh T, Matsumoto K, Oki A, Saida T, et al. Diversity in
size and signal intensity in multilocular cystic ovarian masses: new parameters
for distinguishing metastatic from primary mucinous ovarian neoplasms.
J Magn Reson Imaging. 2013;38:794–801.
3. Pinto PB, Derchain SF, Andrade LA. Metastatic mucinous carcinomas in the
ovary: a practical approach to diagnosis related to gross aspects and to
immunohistochemical evaluation. Int J Gynecol Pathol. 2012;31:313–8.
4. Khunamornpong S, Suprasert P, Pojchamarnwiputh S, Na Chiangmai W,
Settakorn J, Siriaunkgul S. Primary and metastatic mucinous adenocarcinomas
of the ovary: Evaluation of the diagnostic approach using tumor size and
laterality. Gynecol Oncol. 2006;101:152–7.
5. Jung ES, Bae JH, Lee A, Choi YJ, Park JS, Lee KY. Mucinous adenocarcinoma
involving the ovary: comparative evaluation of the classification algorithms
using tumor size and laterality. J Korean Med Sci. 2010;25:220–5.
6. Choi HJ, Lee JH, Seo SS, Lee S, Kim SK, Kim JY, et al. Computed tomography
findings of ovarian metastases from colon cancer: comparison with primary
malignant ovarian tumors. J Comput Assist Tomogr. 2005;29:69–73.
7. Kim SHKW, Park KH, Lee JK, Kim JS. CT and MR findings of Krukenberg tumors:
comparison with primary ovarian tumors. J Comput Assist Tomogr.
1996;20:393–8.
8. La Fianza AAE, Pistorio A, Generoso P. Differential diagnosis of Krukenberg
tumors using multivariate analysis. Tumori. 2002;88:284–7.
9. Bazot M, Darai E, Nassar-Slaba J, Lafont C, Thomassin-Naggara I. Value of
magnetic resonance imaging for the diagnosis of ovarian tumors: a review.
J Comput Assist Tomogr. 2008;32:712–23.
10. Thomassin-Naggara I, Balvay D, Aubert E, Darai E, Rouzier R, Cuenod CA, et al.
Quantitative dynamic contrast-enhanced MR imaging analysis of complex
adnexal masses: a preliminary study. Eur Radiol. 2012;22:738–45.
11. Ma FH, Cai SQ, Qiang JW, Zhao SH, Zhang GF, Rao YM. MRI for differentiating
primary fallopian tube carcinoma from epithelial ovarian cancer. J Magn Reson
Imaging. 2014. doi:10.1002/jmri.24740.
12. Cai SQ, Ma FH, Qiang JW, Zhao SH, Zhang GF, Rao YM. Primary Fallopian
Tube Carcinoma: Correlation Between Magnetic Resonance and Diffuse
Weighted Imaging Characteristics and Histopathologic Findings. J Comput
Assist Tomogr 2014, Published Online First.
13. Zhang H, Zhang GF, Wang TP. Value of 3.0 T diffusion-weighted imaging in
discriminating thecoma and fibrothecoma from other adnexal solid masses.
J Ovarian Res. 2013;6:58.
14. Zhang H, Zhang GF, He ZY, Li ZY, Zhu M, Zhang GX. Evaluation of primary
adnexal masses by 3T MRI: categorization with conventional MR imaging
and diffusion-weighted imaging. J Ovarian Res. 2012;5:33.
15. Zhang H, Zhang GF, He ZY, Li ZY, Zhang GX. Prospective evaluation of 3T
MRI findings for primary adnexal lesions and comparison with the final
histological diagnosis. Arch Gynecol Obstet. 2014;289:357–64.
16. Zhao SH, Qiang JW, Zhang GF, Ma FH, Cai SQ, Li HM, et al. Diffusion-weighted
MR imaging for differentiating borderline from malignant epithelial tumours of
the ovary: pathological correlation. Eur Radiol. 2014;24:2292–9.
17. Zhao SH, Qiang JW, Zhang GF, Boyko OB, Wang SJ, Cai SQ, et al. MRI
appearances of ovarian serous borderline tumor: pathological
correlation. J Magn Reson Imaging. 2014;40:151–6.
18. Ma FH, Zhao SH, Qiang JW, Zhang GF, Wang XZ, Wang L. MRI appearances
of mucinous borderline ovarian tumors: pathological correlation. J Magn
Reson Imaging. 2014;40:745–51.
19. Sohaib SA, Sahdev A, Van Trappen P, Jacobs IJ, Reznek RH. Characterization
of adnexal mass lesions on MR imaging. AJR Am J Roentgenol.
2003;180:1297–304.
20. Liao XY, Huang GJ, Gao C, Wang GH. A meta-analysis of serum cancer antigen
125 array for diagnosis of ovarian cancer in Chinese. J Cancer Res Ther.
2014;10(Suppl):C222–4. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Xu et al. Journal of Ovarian Research  (2015) 8:61 Page 6 of 6
